Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $8.50 Average PT from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

Several research firms recently commented on CNTA. Evercore ISI initiated coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, June 21st. They set an “outperform” rating for the company. SVB Securities upped their price objective on shares of Centessa Pharmaceuticals from $6.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, August 15th. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 15th. The Goldman Sachs Group upped their price objective on shares of Centessa Pharmaceuticals from $4.50 to $5.00 and gave the company a “neutral” rating in a research note on Tuesday, August 15th. Finally, BMO Capital Markets increased their price target on shares of Centessa Pharmaceuticals from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 25th.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. BVF Inc. IL boosted its holdings in shares of Centessa Pharmaceuticals by 36.7% in the first quarter. BVF Inc. IL now owns 9,423,215 shares of the company’s stock valued at $36,279,000 after buying an additional 2,528,870 shares during the period. EcoR1 Capital LLC lifted its position in shares of Centessa Pharmaceuticals by 7.4% in the first quarter. EcoR1 Capital LLC now owns 5,618,779 shares of the company’s stock worth $21,632,000 after purchasing an additional 386,500 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Centessa Pharmaceuticals by 13.3% in the second quarter. Point72 Asset Management L.P. now owns 2,011,388 shares of the company’s stock worth $12,450,000 after purchasing an additional 235,906 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Centessa Pharmaceuticals by 31.7% in the second quarter. Affinity Asset Advisors LLC now owns 900,723 shares of the company’s stock worth $5,575,000 after purchasing an additional 216,596 shares in the last quarter. Finally, Woodline Partners LP lifted its position in shares of Centessa Pharmaceuticals by 10.2% in the first quarter. Woodline Partners LP now owns 882,633 shares of the company’s stock worth $7,917,000 after purchasing an additional 81,497 shares in the last quarter. 73.92% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 4.7 %

CNTA stock opened at $7.06 on Friday. The stock has a market capitalization of $672.82 million, a P/E ratio of -3.90 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.35 and a current ratio of 10.35. Centessa Pharmaceuticals has a one year low of $3.00 and a one year high of $8.65. The company has a 50 day moving average price of $7.02 and a two-hundred day moving average price of $5.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, August 14th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.17. As a group, sell-side analysts expect that Centessa Pharmaceuticals will post -1.74 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.